

November 21, 2019

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

The Bombay Stock Exchange Ltd.
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001

Dear Sirs,

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

--0--

Pursuant to Regulation 23 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are filing herewith Disclosure of Related Party Transactions during the half year ended on September 30, 2019 on a consolidated basis, in the format specified in the accounting standards, and the same is also available on the website of the Company viz, www.thyrocare.com.

Please take the same on record.

Yours Faithfully,

For Thyrocare Technologies Limited,



Ramjee Dorai
Company Secretary and Compliance Officer



Thyrocare Technologies Limited

Thyrocare Technologies Limited

Notes to the standalone financial statements

for the half year ended 30 September 2019

Currency: In crore of INR

36 Related parties

A. Details of related parties:

| Description of relationship | Names of related parties |
|---|--|
| <i>Subsidiary</i> | Nuclear Healthcare Limited |
| <i>Associates</i> | Equinox Labs Private Limited (From 28 March 2018) Thyrocare International Holding Company Limited, Mauritius |
| <i>Enterprise over which directors and their relatives exercise control or influence, where transactions have taken place during the year</i> | Thyrocare Gulf Laboratories WLL Sumathi Infra Project LLP Sumathi Construction Private Limited Mahima Advertising LLP Thyrocare Properties & Infrastructure Private Limited Thyrocare Publications LLP Pavilion Commercial Private Limited |
| <i>Key Management Personnel (KMP)</i> | Dr. A Velumani, Managing Director A. Sundararaju, Director Amruta Velumani, Director |
| <i>Relatives of KMP</i> | Dr. A Velumani HUF (HUF in which Dr. A Velumani is Karta) Amruta Velumani (daughter of Dr. A Velumani) Anand Velumani (son of Dr. A Velumani) A Sundararaju HUF (HUF in which A Sundararaju is Karta) S Susila (sister of Dr. A Velumani) |



B. Transactions with key management personnel

i. Key management personnel compensation

| | Transactions for the half year ended 30 September 2019 | Balance outstanding |
|----------------|--|---------------------|
| Dr. A Velumani | (0.00)* | (0.00)* |
| A Sundararaju | 0.30 | 0.04 |
| | <u>0.30</u> | <u>0.04</u> |

* Amount less than Rs. 0.01 crore

As the liabilities for defined benefit plans are provided on actuarial basis for the Company as a whole, the amount pertaining to key managerial personnel are not separately determined and hence not included in the above amounts.

ii. Transactions with key management personnel including directors

| | Transactions for the half year ended 30 September 2019 | Balance outstanding |
|----------------------|--|---------------------|
| Dividend paid | | |
| Dr A Velumani | 29.62 | - |
| A Sundararaju | 0.50 | - |
| Amruta Velumani | 1.51 | - |

C. Related party transaction other than those with key management personnel

| | Transactions for the half year ended 30 September 2019 | Balance outstanding |
|---|--|---------------------|
| Rent Paid / payable | | |
| Sumathi Construction Private Limited | 0.32 | - |
| Nuclear Healthcare Limited | 0.36 | - |
| Rent received / receivable | | |
| Nuclear Healthcare Limited | 0.32 | - |
| Outlab processing charges paid / payable | | |
| Equinox Labs Private Limited | (0.00)* | 0.03 |



C. Related party transaction other than those with key management personnel (continued)

| | Transactions for the half year ended 30 September 2019 | Balance outstanding |
|--|---|---------------------|
| Revenue from operations | | |
| Thyrocare Gulf Laboratories WLL | 1.82 | 2.71 |
| Nuclear Healthcare Limited | 0.50 | 0.27 |
| Repayment of loans by subsidiary | | |
| Nuclear Healthcare Limited | 25.00 | 14.00 |
| Interest received | | |
| Nuclear Healthcare Limited | 1.76 | 1.76 |
| Reimbursement of expenses (received) | | |
| Nuclear Healthcare Limited | 0.28 | - |
| Thyrocare Gulf Laboratories WLL | 0.19 | |
| Reimbursement of expenses (paid) | | |
| Nuclear Healthcare Limited | 0.20 | 0.02 |
| Sumathi Construction Private Limited | 0.26 | 0.04 |
| Technical assistance fees income | | |
| Thyrocare Gulf Laboratories WLL | 0.53 | 2.56 |
| Dividend paid | | |
| Anand Velumani | 1.27 | - |
| Dr A Velumani HUF | 2.84 | - |
| A Sundararaju HUF | 4.83 | - |
| Sumathi Infra Project LLP | 3.15 | - |
| Mahima Advertising LLP | 2.52 | - |
| Thyrocare Properties & Infrastructure Private Limited | 10.44 | - |
| Thyrocare Publications LLP | 13.07 | - |
| Pavilion Commercial Private Limited | 0.02 | - |
| Investment in equity instruments | | |
| Equinox Labs Private Limited | - | 20.00 |
| Nuclear Healthcare Limited | - | 194.67 |
| Thyrocare International Holding Company Limited, Mauritius | - | 1.61 |
| Security deposit taken | | |
| Nuclear Healthcare Limited | - | 1.15 |
| Security deposit given | | |
| Nuclear Healthcare Limited | - | 0.19 |



Notes :

- i. The key management personnel, or their related parties, hold position in other entities that result in them having control or significant influence over these entities. These entities transacted with the Company during the reporting period. The terms and conditions of the transactions with key management personnel and their related parties were no more favourable than those available, or those which might reasonably be expected to be available, in respect of similar transactions with non-key management personnel entities.

- iii. Thyrocare International Holding Company was in the process of liquidation and the process of liquidation has been completed though the Company is yet to receive the liquidation proceeds due to pending compliance.

